Experience With an Adult Alcohol Withdrawal Syndrome Practice Guideline in Internal Medicine Patients

Karen M. Stanley, MS; Cathy L. Worrall, PharmD, FAPhA; Shayna L. Lunsford, MS; Kit N. Simpson, Dr.PH; Justin G. Miller, MD; Anne P. Spencer, PharmD


Pharmacotherapy. 2005;25(8):1073-1083. 

In This Article


This pilot project suggests that internal medicine patients at risk for AWS can be managed with a standardized, symptom-triggered approach using decreased amounts of benzodiazepine in combination with adjunctive agents to treat adrenergic hyperactivity and delirium. Further data are necessary to determine the impact of the practice guideline on patient outcome measurements.

Presented at the Fall Educational Conference of the International Nurses Society on Addictions and the Association for Medical Education and Research in Substance Abuse, Baltimore, Maryland, November 7, 2003, and at the Clinical Pearls and Professor Poster Rounds sessions of the annual meeting of the American Pharmaceutical Association, Seattle, Washington, March 26-30, 2004.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.